Repare Therapeutics INC 8-K filings

Repare Therapeutics Inc. announced the completion of its acquisition by XenoTherapeutics, Inc., with shareholders receiving cash and contingent value rights.

Repare Therapeutics shareholders overwhelmingly approved the acquisition of the company by XenoTherapeutics, Inc. via a plan of arrangement.

Repare Therapeutics Inc. announced the sale of its RP-3467 program assets to Gilead Sciences, Inc. for up to $30 million, increasing the estimated cash payout for its pending acquisition by XenoTherapeutics.

Repare Therapeutics' Chief Scientific Officer, Dr. Michael Zinda, has resigned effective December 31, 2025, as the company prepares for its acquisition by XenoTherapeutics.

Repare Therapeutics Inc. will be acquired by XenoTherapeutics, Inc. for an estimated $1.82 per share in cash plus contingent value rights, marking the culmination of its strategic wind-up.

Repare Therapeutics Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc., offering shareholders an estimated US$1.82 per share plus contingent value rights.

Repare Therapeutics announced the release of preliminary Phase 1 LIONS trial data for its cancer therapeutic RP-1664, ahead of its presentation at a major oncology conference.

Repare Therapeutics reported second-quarter 2025 financial results, highlighted by new licensing agreements for lunresertib and discovery platforms, alongside an ongoing strategic review to maximize shareholder value.

Repare Therapeutics has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. for its precision oncology product candidate, lunresertib, securing an upfront payment and significant potential milestones.

Repare Therapeutics Inc. has approved an amendment to the severance benefits for its Executive Vice President and Chief Scientific Officer, Michael Zinda, Ph.D., enhancing his compensation package under specific termination scenarios.

Repare Therapeutics Inc. announced that its shareholders approved all three proposals at the 2025 Annual Meeting, including the election of four Class II directors, advisory approval of executive compensation, and the appointment of Ernst & Young LLP as independent auditors.

Repare Therapeutics Inc. filed an amendment to its current report on Form 8-K to disclose the employment agreement for its Senior Vice President, Chief Accounting Officer, Sandra Alves, outlining her compensation and severance terms.

Repare Therapeutics reports Q1 2025 financial results, highlights strategic alternatives to enhance shareholder value, and provides clinical pipeline updates.

Repare Therapeutics has out-licensed its discovery platforms to DCx Biotherapeutics for $4 million upfront, a 9.99% equity stake, and potential future milestone payments and royalties.

Repare Therapeutics announced that Steve Forte has been appointed as President and CEO, succeeding Lloyd Segal, who resigned to pursue other opportunities, effective April 11, 2025.

Repare Therapeutics is focusing on Phase 1 clinical trials, reducing its workforce by 75%, and expects key clinical readouts in 2025 while extending its cash runway into late 2027.

Repare Therapeutics is reducing its workforce by 75% and realigning its clinical portfolio to focus on RP-1664 and RP-3467, leading to the departure of its Chief Medical Officer.

Repare Therapeutics is re-prioritizing its clinical portfolio to focus on Phase 1 programs, seeking partnerships for other assets, and implementing cost reductions to extend its cash runway into mid-2027.

Repare Therapeutics reports promising data from its MYTHIC Phase 1 trial, showing significant response rates for a combination therapy in patients with endometrial and platinum-resistant ovarian cancers.

Repare Therapeutics announced its Q3 2024 financial results and provided updates on its clinical programs, including plans to report data from the MYTHIC trial in December 2024 and begin a registrational trial in 2025.

Repare Therapeutics is streamlining its operations by reducing its workforce by 25% to focus on advancing its four clinical-stage oncology programs.

Repare Therapeutics Inc. reports the resignation of a director and chair of the Science and Technology Committee, with a replacement appointed effective August 6, 2024.

Repare Therapeutics announced its Q2 2024 financial results and provided updates on its clinical programs, including a reiterated timeline for key data readouts.

Repare Therapeutics held its 2024 Annual Meeting of Shareholders, where shareholders voted on the election of directors, executive compensation, and the appointment of an independent accounting firm.

Repare Therapeutics announced encouraging clinical trial progress, including reduced anemia rates in a key study and the initiation of new trials, alongside a strong cash position to support operations through mid-2026.

Repare Therapeutics has announced that Todd Foley will not seek re-election to the board, and Steven H. Stein, M.D. will join as a new director.

Repare Therapeutics announced its 2023 financial results and provided a business update, showcasing advancements in its clinical programs and strategic collaborations.

Repare Therapeutics will regain full control of its camonsertib program after Roche terminated their collaboration agreement, effective May 7, 2024.

Repare Therapeutics has received a $40 million milestone payment from Roche following the first patient being dosed with camonsertib in Roche's TAPISTRY trial.

Repare Therapeutics provided a corporate update, highlighting significant pipeline advancements and anticipated milestones for 2024, including the expansion to four clinical-stage programs.